Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD1704 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD1704 | DRUG | One dose, by mouth |
Inclusion Criteria: * Healthy volunteers, man or woman of non child-bearing potential * Provision of signed informed consent. Exclusion Criteria: * History of somatic disease/condition that may interfere with the objectives ot the study, as judged by the Investigator. History of seizures, with th...
AZD1704 is an investigational small molecule being developed for the treatment of pain. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.
AZD1704 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to investigate the drug's potential as a treatment for pain.
AZD1704 is in Phase 1 clinical development. A Phase 1 trial has been completed to assess the safety, tolerability, and pharmacokinetics of a single ascending dose of the drug. It remains an investigational agent and is not yet approved for any use.
AZD1704 has one completed Phase 1 clinical trial registered as NCT00692042, titled "Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704." The trial enrolled 80 participants in the United Kingdom and included healthy volunteers aged 20 years and older.
AZD1704 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of pain. The completed Phase 1 trial focused on safety, tolerability, and pharmacokinetics, and further clinical studies would be needed before any regulatory approval could be considered.